Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT

Exclusion Criteria

• •1. Active bacterial or fungal infection (confirmed by imaging diagnosis or bacteriological examination with fever \>38°C).
• •2. Multiple active cancers (synchronous or metachronous multiple primary cancers, excluding in situ carcinoma or intramucosal cancer lesions considered cured by local treatment; such lesions are not included in active multiple cancers).
• •3. Patients with severe impairment of cardiac, hepatic, or renal function (cardiac function grade 3-4; ALT and/or AST more than 3 times the upper limit of normal; Cr exceeding the upper limit of normal).
• •4. Patients with concomitant other malignant tumors or hematological diseases.
• •5. Pregnant, planning to become pregnant, or lactating female patients (diagnosed with early pregnancy when urine HCG \>2500 IU/L).
• •6. Any form of antitumor therapy before tumor resection, including interventional chemotherapy embolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy.
• •7. Patients who participated in other tumor-related clinical trials within the past three months.
• •8. Preoperative CT suggests ground-glass predominant nodules (CTR \< 0.5).
• •9. Patients with positive lymph nodes indicated by preoperative imaging or lymph node puncture (clinical N stage = 1 or 2).
• •10. Patients with tumors near the hilum who cannot undergo segmentectomy.
• •11. Patients deemed unsuitable for enrollment by the investigator.
• •1. Patients with IASLC grade 3 (≥20% pathological high-grade subtypes) indicated by intraoperative frozen section.
• •2. Patients confirmed with in situ carcinoma or microinvasive adenocarcinoma by intraoperative frozen section.
• •3. Patients with preoperative findings of distant metastasis or pleural/ascitic effusion.